Friday, July 11, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Merck: Great Medicine For The Portfolio (NYSE:MRK)

by Euro Times
October 30, 2022
in Business
Reading Time: 4 mins read
A A
0
Home Business
Share on FacebookShare on Twitter


JHVEPhoto

In August of last year I concluded that Merck (NYSE:MRK) showed a “murky non-Keytruda” performance. Despite non-Keytruda sales being not that inspiring, I believed that overall valuations and expectations were low, making me hold a position in shares with great conviction.

Since this period of time, shares have risen some 30% which in itself is impressive enough, but it’s certainly a big result if we factor in the disappointing performance of the market at large since this period of time.

Former Take

Ahead of the pandemic, Merck was a business which generated nearly $47 billion in sales in 2019 on which it earned $5.19 per share. Being an $80 stock, valuations were not too demanding at just 15-16 times earnings, certainly as the company guided for 2020 sales to rise to roughly $49 billion, with earnings seen around $5.70 per share. The reason for the non-demanding multiples was the fact and curse that Merck has Keytruda in its product line, a hugely successful drug, with investors clearly worried about its growing reliance as well.

The pandemic held the company back in a minor extent. In the end, sales were up 2% to $48 billion, albeit that reliance on Keytruda rose as its sales rose 30% to $14.4 billion that year. Comforting was the 2021 guidance, calling for sales to rise to nearly $53 billion with earnings seen in excess of $6.50 per share. With shares trading in the seventies, the overall valuation was very low, certainly as we found ourselves in a low interest rate environment at the time, making me compelled to shares in the seventies, as I kept adding to my stake.

The company updated the guidance throughout the year, seeing sales at $47 billion if we strip out the $6 billion revenue contribution from Organon (OGN) which was spun off, as earnings were seen down to $5.50 per share. The deal furthermore allowed Merck to cut net debt to $18 billion, resulting in a very modest leverage number. The only downfall is that the reliance on Keytruda kept rising, creeping up to mid-thirties percentages.

Despite this reliance, and non-inspiring growth outside Keytruda, I was appealed to Merck given the strong balance sheet, full pipeline and non-demanding valuation.

Moving Up

With shares range bound around the $80 mark since August of last year, shares have recently seen quite momentum, trading up to $100 right now, as shares are finally breaking through their highs set around the 2000s.

Earlier this year the company posted a very strong $48.7 billion in annual revenue number (essentially $55 billion including Organon), up 17% on the year before. Keytruda sales were up 20% to $17.2 billion, increasing its share to 35% of sales. Non-GAAP earnings came in at $6.02 per share, coming in ahead of the guidance by a comfortable margin.

The company furthermore guided for a very strong 2022 with sales seen at a midpoint of $56.8 billion and earnings seen around $7.20 per share (on an adjusted basis).

The company started the year in a spectacular fashion with first quarter sales up 50% to $15.9 billion, as the company hiked the full-year midpoint of the guidance to $57.5 billion in sales. The $4.8 billion quarterly revenue contribution from Keytruda was a huge driver behind this growth, up 23% on the year before. The real contribution came from LAGEVRIO. This anti COVID-19 treatment drug generated $3.2 billion in sales in the quarter.

Second quarter sales rose 28% to $14.6 billion, including a much more modest $1.2 billion LAGEVRIO revenue contribution. The midpoint of the full year revenue guidance was hiked to $58 billion, despite intensifying headwinds from a strong dollar.

Third quarter sales were up 14% to $15.0 billion, with LAGEVRIO sales down to just $436 million. Excluding this revenue contribution, revenue growth came in at 10%, but this included a 4% headwind from the strong dollar. Comforting is that growth outside Keytruda has accelerated to high single digits, comforting as a $5.4 billion revenue contribution of Keytruda (at $22 billion a year here) increases the reliance on this drug further, driven by wider adoption and approvals, it must be said.

Full-year sales are now seen between $58.5 and $59 billion. This suggests fourth quarter revenues between $13.1 and $13.6 billion which feels a bit light. This is seen in the earnings guidance as well, as a non-GAAP earnings number of $5.86 per share so far this year is set only to rise to $7.35 per share for the year.

No 10-Q filling was filed so far for the third quarter, as net debt stood at $21 billion and change through the second quarter of the year.

Concluding Remark

The reality is that the market shift from growth to value has resulted in a re-rating of Merck’s valuation, aided by solid growth so far this year. A 12-13 times multiple based on $6 per share earnings power last year has expanded to about 14 times earnings of just over $7 per share here. Hence, growth is driven by a higher valuation multiple and earnings growth, driven by the superior performance of the business. Of course this is still largely driven by Keytruda, yet non-Keytruda sales are starting to increase again, albeit that the reliance on Keytruda keep increasing following rapid growth in sales of this particular product.

Right now the situation is quite stable and upbeat around Merck here, as the company is in full execution mode. The goal is to simply execute here, deleverage and perhaps pursue bolt-on dealmaking. Of course, we have seen rumors about a Seattle Genetics (SGEN) deal this past summer, a potential massive deal in which the target could be valued at $40 billion. This is of course an astonishing amount, although Merck’s valuation has risen to $270 billion.

Right now, given the outperformance and slightly higher multiple in a rapidly raising interest rate, I see no reason to add to my position here, yet find it too early to go profit taking, leaving me cautiously sitting on my position which carries very decent gains.



Source link

Tags: GreatMedicineMerckNYSEMRKPortfolio
Previous Post

Here’s Why The Fast-Recovering Chiliz Price May Hit $0.255 Mark

Next Post

RNC Chair Ronna McDaniel Blames ‘Democratic Policies’ for Pelosi Attack

Related Posts

Elon Musk’s SpaceX set to launch Israel’s Dror satellite

Elon Musk’s SpaceX set to launch Israel’s Dror satellite

by Assaf Gilead
July 11, 2025
0

On Sunday morning US billionaire Elon Musk's SpaceX's Falcon 9 rocket will launch Israel Aerospace Industries (IAI) Dror 1...

Apple iPhone 16e, Samsung Galaxy S24 Ultra, OnePlus Nord 5

Apple iPhone 16e, Samsung Galaxy S24 Ultra, OnePlus Nord 5

by NDTV Profit Tech
July 11, 2025
0

4. iQOO 13 (Ace Inexperienced): Rs 52,999 (Down From Rs 61,999)Outfitted with a 6,000mAh battery, 6.82-inch FHD display screen, 50MP...

Crude oil futures gain as Trump plans major Russia statement 

Crude oil futures gain as Trump plans major Russia statement 

by Euro Times
July 11, 2025
0

At 9.53 am on Friday, September Brent oil futures have been at $68.79, up by 0.22%, and August crude oil...

US stocks: S&P 500, Nasdaq rise to record highs boosted by Nvidia record valuation, strong Delta forecast

US stocks: S&P 500, Nasdaq rise to record highs boosted by Nvidia record valuation, strong Delta forecast

by Euro Times
July 11, 2025
0

The S&P 500 and the Nasdaq Composite rose modestly to publish file closing highs on Thursday, boosted by an upbeat...

Furniture Insider: Data and Trends for Resellers (2025)

Furniture Insider: Data and Trends for Resellers (2025)

by Andrea Vargas
July 10, 2025
0

The furnishings class is rapidly increasing in each quantity and recognition. Main manufacturers and retailers depend on B-Inventory—the world’s largest...

Saratoga Investment Q1: ROE Beating The BDC Industry Average (NYSE:SAR)

Saratoga Investment Q1: ROE Beating The BDC Industry Average (NYSE:SAR)

by David Johnson
July 10, 2025
0

This text was written byObserveDavid A. Johnson is founder and principal of Endurance Capital Administration, a New Jersey Restricted Legal...

Next Post
RNC Chair Ronna McDaniel Blames ‘Democratic Policies’ for Pelosi Attack

RNC Chair Ronna McDaniel Blames 'Democratic Policies' for Pelosi Attack

Weekly MacroSlate: Have U.S. treasury yields and the DXY topped for this cycle? Big miss for big tech as Bitcoin holds steady at k

Weekly MacroSlate: Have U.S. treasury yields and the DXY topped for this cycle? Big miss for big tech as Bitcoin holds steady at $20k

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Why ACA health insurance premiums may see ‘sharp’ increase in 2026

Why ACA health insurance premiums may see ‘sharp’ increase in 2026

July 11, 2025
PEP, Supportive Care, and More

PEP, Supportive Care, and More

July 11, 2025
Research Predicts 0,000 Bitcoin By EOY, If Treasury Firms Hold

Research Predicts $160,000 Bitcoin By EOY, If Treasury Firms Hold

July 11, 2025
Russia develops Mi-80 to replace iconic Hip helicopter

Russia develops Mi-80 to replace iconic Hip helicopter

July 11, 2025
Elon Musk’s SpaceX set to launch Israel’s Dror satellite

Elon Musk’s SpaceX set to launch Israel’s Dror satellite

July 11, 2025
Corn Sticking Close to Unchanged at Midday

Corn Sticking Close to Unchanged at Midday

July 11, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Why ACA health insurance premiums may see ‘sharp’ increase in 2026

PEP, Supportive Care, and More

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In